Although clinical manifestations of the 2019 novel coronavirus disease pandemic (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), are mainly respiratory symptoms, patients can also develop severe cardiovascular damage. Therefore, understanding the damage caused by SARS-COV-2 to the cardiovascular system and the underlying mechanisms is fundamental. The cardiovascular damage may be related to the imbalance of the renin-angiotensin-system (RAS) as this virus binds the Angiotensin-Converting-Enzyme 2 (ACE2), expressed on the lung alveolar epithelial cells, to enter into cells. Virus internalization may cause a downregulation of ACE2 on host cell surface that could lead to a local increased level of angiotensin II (AII) and a reduced level of angiotensin 1-7 (A1-7). An imbalance between these angiotensins may be responsible for the lung and heart damage. Pharmacological strategies that interfere with the viral attachment to ACE2 (umifenovir and hydroxychloroquine/chloroquine) or that modulate the RAS (analogous of A1-7 and ACE2, losartan) are in clinical development for COVID-19. The use of RAS inhibitors has also become a matter of public concern as these drugs may increase the mRNA expression and levels of ACE2 and impact the virulence and transmission of SARS-COV-2. Data on the effect of RAS inhibitors on ACE2 mRNA expression are scarce. Scientific societies expressed their opinion on continuing the therapy with RAS inhibitors in patients with COVID-19 and underlying cardiovascular diseases. In conclusion, RAS may play a role in SARS-COV-2-induced cardiac and pulmonary damage. Further studies are needed to better understand the role of RAS in COVID-19 and to guide decision on the use of RAS inhibitors.
【저자키워드】 COVID-19, SARS-CoV-2, renin-angiotensin system, RAS inhibitors, Heart damage, pulmonary damage, 【초록키워드】 ACE2, coronavirus, pandemic, therapy, lung, Local, Transmission, cardiovascular diseases, drug, cardiovascular system, virus, RAS, 2019 novel coronavirus, cells, Patient, epithelial cells, umifenovir, virulence, disease, expression, mechanism, Angiotensin 1-7, losartan, respiratory symptoms, clinical manifestation, acute respiratory syndrome, ACE2 mRNA, cardiovascular damage, clinical development, downregulation, mRNA expression, hydroxychloroquine/chloroquine, host cell surface, bind, responsible, develop, caused, reduced, expressed, modulate, interfere, lung alveolar, patients with COVID-19, RAS inhibitor, 【제목키워드】 review, narrative, System,